AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden, to support accelerating biologics portfolio

Monday, 18 May 2015

AstraZeneca today announced that it plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics. It is anticipated that the new facility will supply medicines for clinical trial programmes of AstraZeneca and MedImmune, the company’s global biologics research and development arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019.

Södertälje is currently home to AstraZeneca’s largest global tablets and capsules manufacturing facility and is also a launch platform site for the company, with specialist capabilities on-site that allow large-scale production of new medicines, working closely with the research and development organisation. By locating the new manufacturing plant in Södertälje, the company will combine its expertise in biologics with the well-established culture of operational excellence that exists within the Sweden Operations unit.

The planned investment will, subject to relevant approvals by the local authorities, create between 150 and 250 highly skilled new roles at AstraZeneca by 2019.

Pascal Soriot, Chief Executive Officer, said: “This is a strategically important investment for AstraZeneca to support the accelerating development of biotech medicines, which now make up around half of our pipeline. We expect to bring a significantly increased number of new specialty care medicines to patients in the coming years, driven in large part by biologics. This new plant will give us greater capacity and flexibility to handle clinical trials, and will also play an important role in our future commercial production."

The $285 million planned investment is the first phase of a potential three-part programme to expand AstraZeneca’s biologics manufacturing capabilities. Further investment decisions are expected to be made in the coming years.

Jan-Olof Jacke, President, AstraZeneca AB, said: “Building what will be a world-class facility in this area is not only important to AstraZeneca but we believe it will also add value to the Swedish and Nordic life sciences sector by enhancing the skills base. Södertälje will also be considered as the location for the next phases of our programme to expand our global biologics manufacturing capacity. In addition to our strong internal capabilities and the access to a highly skilled workforce within the life science sector, we are encouraged by signals from the Swedish Government regarding a competitive and supportive environment for business investment."

The new manufacturing facility in Sweden will support the progression of drug candidates across the main therapy areas and be aligned with investments being made in the current biologics manufacturing centers, such as the expansion in Frederick, Maryland, announced in November.



About AstraZeneca in Södertälje

In Södertälje AstraZeneca has one of the largest production sites for medicines in the world. Our facilities are located in Snäckviken and Gärtuna, where the new facility will be located. Södertälje is also the location for the headquarters of AstraZeneca’s Nordic-Baltic marketing company, as well as a number of enabling functions. 3,800 roles are currently based here. The medicines delivered from Sweden Operations account for approximately 35% of AstraZeneca’s total sales value. In 2013, AstraZeneca’s exports of medicines from Sweden totaled 39 billion SEK, which accounts for approximately 3.5% of the total Swedish export of goods.

About AstraZeneca in biologics

Biologics are in development across all our therapy areas. We are transforming our business to become more sustainable, durable and profitable by focusing on specialty care medicines, devices and biologics. Biologics, or large molecules, now account for half our pipeline, including more than 30 molecules in clinical development. Much of our biologics work focuses on specifically defined or biologically targeted populations, determined by the scientific pathway of the disease and mode of action of the molecule. Biologics have revolutionised medicine, treating complex diseases including various types of cancer and autoimmune disorders. The use of biologics has become an important source of innovation and an increasing proportion of the most commercially successful new drugs on the market today are biologics.

About MedImmune

MedImmune is the worldwide biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres. For more information, please visit:

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:



Media Enquiries    
Esra Erkal-Paler (UK/Global) +44 20 7604 8030
Vanessa Rhodes (UK/Global) +44 20 7604 8037
Ayesha Bharmal (UK/Global) +44 20 7604 8034
Jacob Lund (Sweden) +46 8 553 260 20
Michele Meixell (US)
+1 302 885 6351


Investor Enquiries UK    
Thomas Kudsk Larsen +44 20 7604 8199 mob: +44 7818 524185

Eugenia Litz

(Respiratory, Inflammation and Autoimmunity)

+44 20 7604 8233 mob: +44 7884 735627

Nick Stone

(Cardiovascular and Metabolic Disease)

+44 17 6326 3994 mob: +44 7717 618834

Karl Hård


+44 20 7604 8123 mob: +44 7789 654364

Craig Marks

(Infection, Neuroscience and Gastrointestinal Disease)

+44 20 7604 8591 mob: +44 7881 615764
Christer Gruvris +44 20 7604 8126 mob: +44 7827 836825


  • Corporate and financial